Sudden Hearing Loss Steroid Treatment

Idiopathic sudden sensorineural hearing loss (ISSNHL) affects 5-20 per 100,000 people annually and represents an otologic emergency. For decades, a wide variety of treatments were tried empirically — vasodilators, antivirals, carbogen inhalation, and steroids — without rigorous evidence for any. The Wilson trial (1980) was an early, small RCT of 67 patients comparing oral prednisone to placebo, showing a modest benefit for steroids in patients with moderate hearing loss. Despite its small size and methodological limitations, this trial established oral corticosteroids as the de facto standard treatment, largely because no better alternatives existed. The mechanism was presumed to be reduction of cochlear inflammation and immune-mediated damage, though the etiology of ISSNHL remains poorly understood in most cases.

The Rauch trial, published in the New England Journal of Medicine in 2011, was the most important modern RCT for ISSNHL treatment. This multicenter trial randomized 250 patients to oral prednisone versus intratympanic methylprednisolone as primary therapy within 14 days of symptom onset. The key finding was that intratympanic steroids were non-inferior to oral steroids, with comparable hearing recovery across all hearing frequencies and severity subgroups. This established intratympanic steroid injection as a viable alternative for patients who cannot tolerate systemic steroids (diabetics, immunocompromised). The trial also confirmed that approximately 50-60% of patients with ISSNHL recover significant hearing regardless of treatment, reflecting the high spontaneous recovery rate that confounds outcome assessment in this condition.

Subsequent research focused on intratympanic steroids as salvage therapy for patients who fail initial oral steroid treatment. The Battaglia and Slattery trial demonstrated that intratympanic dexamethasone salvage therapy in patients failing oral steroids produced significant hearing improvement compared to no additional treatment. A systematic review by Crane and colleagues confirmed that intratympanic salvage therapy provides additional hearing recovery in approximately 35-40% of patients who fail primary oral steroids. Combination therapy (simultaneous oral plus intratympanic steroids) was evaluated in several RCTs with mixed results — the Battaglia 2008 trial showed benefit of combination therapy, while the Koltsidopoulos 2013 trial did not. Hyperbaric oxygen therapy was studied as an adjunct, with a Cochrane review showing modest potential benefit but insufficient evidence for routine recommendation.

The AAO-HNS Clinical Practice Guideline for Sudden Hearing Loss (2019 update) recommends offering oral corticosteroids as initial therapy within 14 days of symptom onset (Strong recommendation). Intratympanic steroids are recommended as salvage therapy for patients who do not recover with initial oral steroids (Recommendation). The guideline notes that combination therapy (oral + intratympanic) and primary intratympanic therapy are options but with weaker evidence. The guideline emphasizes prompt evaluation with audiometry and MRI to exclude retrocochlear pathology (vestibular schwannoma). The German S1 guideline similarly recommends systemic corticosteroids as first-line and intratympanic steroids as rescue therapy.

The standard of care for ISSNHL is oral corticosteroids (prednisone 1mg/kg/day for 10-14 days with taper) initiated promptly after diagnosis, with intratympanic steroid salvage for patients who do not recover adequately. Despite being the standard treatment, the evidence base for oral steroids remains surprisingly thin — the Wilson 1980 trial is small and old, and the Rauch 2011 trial compared two steroid routes rather than testing against placebo. A large, modern, placebo-controlled trial of oral steroids for ISSNHL has never been conducted, raising the provocative question of whether steroids truly change the natural history or merely coincide with spontaneous recovery. Ongoing research investigates the role of antiviral agents (for suspected viral etiologies), higher steroid doses, extended intratympanic steroid courses, and biomarkers to predict recovery and guide treatment intensity.